Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, Lau O, Calara-Nielsen K, Davis C, Patel J, Banerjee A, Stephenson T, Uhlar C, Kobos R, Goldberg J, Pei L, Trancucci D, Girgis S, Wang Lin SX, Wu LS, Moreau P, Usmani SZ, Bahlis NJ, van de Donk NWCJ, Verona RI.
Cortes-Selva D, et al. Among authors: uhlar c.
Blood. 2024 Aug 8;144(6):615-628. doi: 10.1182/blood.2023022823.
Blood. 2024.
PMID: 38657201
Free PMC article.
Clinical Trial.